| Autor: |
Zimmerman, Robert J., Gauny, Stacey, Chan, Anthony, Landre, Phoebe, Winkelhake, Jeffrey L. |
| Zdroj: |
JNCI: Journal of the National Cancer Institute; 2/3/1989, Vol. 81 Issue 3, p227-231, 5p |
| Abstrakt: |
Simultaneous administration of recombinant human tumor necrosis factor (rhTNF) and interleukin-2 (rhIL-2) has been shown to block tumor take in murine models. We investigated the effects of sequence and schedule of administration as a function of tumor burden with two tumor models (B16 and Meth A). rhTNF followed by rhIL-2 had extraordinary antitumor efficacy, but rhIL-2 followed by rhTNF was much less effective. Sequential rhTNF/rhIL-2 therapy resulted in complete tumor regression, whereas simultaneous therapy resulted in only reduced growth rate. Experiments with genetically immunodeficient mice suggested that T cell factors may be required for synergistic antitumor activity. [J Natl Cancer Inst 1989;81:227–231] [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
